Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : LLY save search
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.03%
H: 1.66%
C: -1.11%
obesity tirzepatide
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
Published: 2024-02-22 (Crawled : 09:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.97%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
trial
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
Published: 2023-10-12 (Crawled : 13:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
disease trial
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-22 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: -0.82%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
keytruda lung merck update cancer cell trials plus
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.06%
H: 0.53%
C: -0.31%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
lancet publication results
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
Published: 2023-05-25 (Crawled : 17:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.14%
H: 0.43%
C: 0.22%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 3.44%
H: 0.0%
C: -5.22%
pharmaceuticals results study
Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 0.89%
C: -0.79%
program
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published: 2023-01-10 (Crawled : 19:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.24%
H: 1.21%
C: 1.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.1%
H: 2.05%
C: 0.82%
ibi362 chinese diabetes study
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published: 2023-01-09 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.02%
H: 0.36%
C: -2.56%
ibi362 chinese diabetes study
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.21%
H: 1.6%
C: 0.72%
jardiance blood children trial diabetes
EMPA-KIDNEY trial showed significant benefit of JARDIANCE (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
Published: 2022-11-04 (Crawled : 22:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
disease kidney trial cardiovascular living jardiance
FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 8.28%
H: 2.44%
C: -19.07%
covid-19 fda sabizabulin granted authorization positive phase 3 emergency use authorization
AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
Published: 2022-04-26 (Crawled : 17:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.34%
H: 1.41%
C: -1.17%
tirzepatide
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Hope Springs Eternal for Inflammatory Disease Treatments at AAD 2022
Published: 2022-03-28 (Crawled : 13:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.8%
H: 0.39%
C: 0.11%
disease treatment
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published: 2022-03-16 (Crawled : 17:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
pos kidney trial positive results positive results
Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR's Next Step
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 7.22%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.08%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
DRRX | $0.9019 -0.89% -0.9% 110K
|
Health Technology
|
| O: -1.84%
H: 1.67%
C: -7.94%
xin crispr cel
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.